GlassScriptPhysician profile
Lori A Steinmann
NPI 1962406413
$6,247.58
in general payments reported to CMS, 2019-2025
44 companies · $893 in 2025
The $893 reported for 2025 was more than what 98% of Advanced Practice Midwife providers received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,940 · 2022: $1,553 · 2023: $966 · 2024: $896 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,754.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,061.64 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $519.53 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $349.32 | 2021-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $318.29 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $273.86 | 2021-2025 | |
| Amgen INC. | $262.54 | 2021-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $232.82 | 2021-2024 | Farxiga |
| Lilly USA, LLC | $195.97 | 2021-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $161.54 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $151.95 | 2021-2024 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $147.11 | 2022 | |
| Astellas Pharma US INC | $134.64 | 2021-2025 | Veozah |
| Abbott Laboratories | $116.51 | 2021-2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $116.33 | 2021-2023 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $104.39 | 2021-2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $96.57 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.16 | 2022-2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $81.59 | 2021-2023 | Seglentis, Livalo |
| Biohaven Pharmaceuticals, INC. | $73.57 | 2021 | |
| Exact Sciences Corporation | $64.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Insulet Corporation | $59.80 | 2024-2025 | Omnipod |
| Cranial Technologies, INC | $48.93 | 2024-2025 | Doc Band |
| Baxter Healthcare | $47.20 | 2022 | |
| Therapeuticsmd, INC. | $43.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $43.48 | 2021-2022 | |
| Itamar Medical INC | $40.92 | 2024-2025 | Watchpatone |
| Merck Sharp & Dohme LLC | $40.56 | 2021 | |
| Neos Therapeutics, LP | $37.58 | 2024 | Adzenys Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $31.96 | 2025 | Rexulti |
| Mdd US Operations, LLC | $31.68 | 2025 | Qelbree |
| Lundbeck LLC | $31.13 | 2022 | |
| Mayne Pharma Commercial LLC | $29.00 | 2023 | |
| Idorsia Pharmaceuticals US INC | $28.80 | 2022-2023 | Quviviq |
| Biomarin Pharmaceutical INC. | $19.65 | 2021 | |
| Dexcom, INC. | $18.71 | 2023 | Dexcom G6 Transmitter |
| Coopersurgical, INC. | $18.57 | 2025 | Paragard T 380a |
| Actelion Pharmaceuticals US, INC. | $17.83 | 2024 | Opsumit, Uptravi |
| Sanofi Pasteur INC. | $17.66 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.59 | 2025 | |
| Alkermes, INC. | $16.55 | 2024 | Aristada, Lybalvi |
| Phathom Pharmaceuticals, INC. | $16.45 | 2024 | Voquezna |
| Seqirus USA INC | $15.65 | 2024 | Flucelvax |
| Kaleo, INC. | $14.27 | 2022 | |
| Eisai INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Steinmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.